Millipore Sigma Vibrant Logo

341209 EUK-8 - CAS 53177-12-1 - Calbiochem

A synthetic salen-manganese complex with high superoxide dismutase (SOD) and catalase-mimic activities, and oxyradical scavenging activities.

EUK-8 - CAS 53177-12-1 - Calbiochem: Ficha de datos de seguridad (MSDS o SDS), certificado de análisis y de calidad (CoA y CoQ), expedientes, folletos y otros documentos disponibles.
View Products on Sigmaaldrich.com
341209
Ver precios y disponibilidad

Descripción

Replacement Information

Tabla espec. clave

CAS #Empirical Formula
53177-12-1C₁₆H₁₄ClMnN₂O₂

Precios y disponibilidad

Número de referencia DisponiblidadEmbalaje Cant./Env. Precio Cantidad
341209-10MG
Comprobando disponibilidad...
—
Disponibilidad a confirmar Disponibilidad a confirmar
Ingrese cantidad 
Suspendido
Cantidades limitadas disponibles
Debe confirmarse disponibilidad
    El resto: se avisará
      El resto: se avisará
      Se avisará
      Póngase en contacto con el Servicio de Atención al Cliente
      Contact Customer Service

      		 Ampolla de plást. 10 mg
      Recuperando precio...
      No pudo obtenerse el precio
      La cantidad mínima tiene que ser múltiplo de
      Maximum Quantity is
      Al finalizar el pedido Más información
      Ahorró ()
       
      —
      Solicitar precio
      		 —
      Description
      OverviewA synthetic salen-manganese complex with high superoxide dismutase (SOD) and catalase-mimic activities, and oxyradical scavenging activities. Shown to have protective effects in numerous models for disease processes associated with oxidative stress, including inflammation, cardiovascular diseases, acute critical illness, autoimmune diseases, and neurological disorders. Useful in preventing cardiac damage caused by ischemic reperfusion. Also prevents β-amyloid peptide (Aβ)-induced free radical formation and lipid peroxidation. Imparts protection against Aβ40 and Aβ42 toxicity in hippocampal cultures.
      Catalogue Number341209
      Brand Family Calbiochem®
      References
      ReferencesColparet, E. E. and Lefebure, R. A. 2000. Br. J. Pharmacol. 130, 359.
      Brandier, C., et al. 1997. J. Vasc. Res. 34, 49.
      Doctrow, S.R., et al. 1997. Adv. Pharmacol. 38, 247.
      Bruce, A.J., et al. 1996. Proc. Natl. Acad. Sci. USA 93, 2312.
      Pucheu, S., et al. 1996. Cardiovasc. Drug Ther. 10, 331.
      Baudry, M., et al. 1993. Biochem. Biophys. Res. Commun. 192, 964.
      Product Information
      CAS number53177-12-1
      ATP CompetitiveN
      DeclarationNot available for sale in Africa, Australia, Great Britain, Europe, Latvia, New Zealand, and the United States.
      FormDark brown solid
      Hill FormulaC₁₆H₁₄ClMnN₂O₂
      Chemical formulaC₁₆H₁₄ClMnN₂O₂
      ReversibleN
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetSuperoxide dismutase (SOD) and catalase-mimic activities, and oxyradical scavenging activities
      Purity≥90% by elemental analysis
      Physicochemical Information
      Cell permeableN
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 weeks at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Número de referencia GTIN
      341209-10MG 04055977215465

      Documentation

      EUK-8 - CAS 53177-12-1 - Calbiochem Ficha datos de seguridad (MSDS)

      Título

      Ficha técnica de seguridad del material (MSDS) 

      EUK-8 - CAS 53177-12-1 - Calbiochem Certificados de análisis

      CargoNúmero de lote
      341209

      Referencias bibliográficas

      Visión general referencias
      Colparet, E. E. and Lefebure, R. A. 2000. Br. J. Pharmacol. 130, 359.
      Brandier, C., et al. 1997. J. Vasc. Res. 34, 49.
      Doctrow, S.R., et al. 1997. Adv. Pharmacol. 38, 247.
      Bruce, A.J., et al. 1996. Proc. Natl. Acad. Sci. USA 93, 2312.
      Pucheu, S., et al. 1996. Cardiovasc. Drug Ther. 10, 331.
      Baudry, M., et al. 1993. Biochem. Biophys. Res. Commun. 192, 964.

      Folleto

      Cargo
      Pathways and Biomarkers of Oxidative Stress
      Ficha técnica

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision24-June-2008 RFH
      DescriptionA synthetic salen-manganese complex with high superoxide dismutase (SOD), catalase, and oxyradical scavenger activities. Shown to have protective effects in numerous models for disease processes associated with oxidative stress, including inflammation, cardiovascular diseases, acute critical illness, autoimmune diseases, and neurological disorders. Useful in preventing cardiac damage caused by ischemic reperfusion. Also prevents β-amyloid peptide (Aβ)-induced free radical formation and lipid peroxidation and imparts protection against Aβ40 and Aβ42 toxicity in hippocampal cultures.
      FormDark brown solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number53177-12-1
      Chemical formulaC₁₆H₁₄ClMnN₂O₂
      Structure formulaStructure formula
      Purity≥90% by elemental analysis
      SolubilityDMSO (20 mg/ml)
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 weeks at -20°C.
      Toxicity Standard Handling
      ReferencesColparet, E. E. and Lefebure, R. A. 2000. Br. J. Pharmacol. 130, 359.
      Brandier, C., et al. 1997. J. Vasc. Res. 34, 49.
      Doctrow, S.R., et al. 1997. Adv. Pharmacol. 38, 247.
      Bruce, A.J., et al. 1996. Proc. Natl. Acad. Sci. USA 93, 2312.
      Pucheu, S., et al. 1996. Cardiovasc. Drug Ther. 10, 331.
      Baudry, M., et al. 1993. Biochem. Biophys. Res. Commun. 192, 964.